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Here we report the activity of liposomes comprising egg phosphatidylcholine (PC) and stearylamine (SA)
against Leishmania donovani parasites. Both promastigotes and intracellular amastigotes in vitro and in vivo
were susceptible to SA-PC liposomes. A single dose of 55 mg of SA-PC liposomes/animal could significantly
reduce the hepatic parasite burden by 85 and 68% against recent and established experimental visceral
leishmaniasis, respectively, suggesting their strong therapeutic potential.
Of the various clinical forms of leishmaniasis, visceral leish-
maniasis, or kala-azar, caused by Leishmania donovani, is the
most severe and often is fatal if untreated. The pentavalent
antimonial agents sodium stibogluconate and meglumine an-
timoniate, although moderately toxic, have remained the stan-
dard treatment for visceral leishmaniasis since the 1940s (5, 9).
However, there are increasing reports of resistance to antimo-
nial agents and high rates of relapses (17). In such cases,
patients are treated with pentamidine or amphotericin B. Al-
though powerful antileishmanial agents, these drugs remain a
second line of defense because of their severe toxicities (3).
However, the antimonial agents, pentamidine, and amphoter-
icin B, when encapsulated in liposomes, are more effective for
the treatment of leishmaniasis and are less toxic than the free
drugs (4, 6, 15). Reduced toxicity and an improved therapeutic
index with liposomal formulations, especially of amphotericin
B, represent an alternative for the treatment of human visceral
leishmaniasis (6, 20).
It was reported earlier that liposomes consisting of stearyl-
amine (SA) and phosphatidylcholine (PC) are cytotoxic toward
Trypanasoma cruzi (23), T. brucei gambiense (18), and Toxo-
plasma gondii (19). This remarkable effect of SA-PC lipo-
somes, although not clearly understood, possibly occurs
through interaction of the positively charged lipids with the
negatively charged parasite membrane. Here we report the
leishmaniacidal activity of SA-PC liposomes on L. donovani
promastigotes and the antileishmanial effect of these lipo-
somes (free of drug) on amastigotes in vitro and in vivo in
murine models of visceral leishmaniasis.
Liposomes were prepared with egg lecithin (PC) (Centre for
Biochemical Technology, Delhi, India) and SA (Fluka, Buchs,
Switzerland) at a molar ratio of 7:2 as described earlier (1).
Briefly, the thin dry film was dispersed in 20 mM phosphate-
buffered saline (PBS) and vortexed, and the suspension was
sonicated for 60 s in an ultrasonicator. The amount of lipo-
somes, expressed as total lipid content, was the sum of the SA
and PC contents. Liposomes containing only PC were pre-
pared as described above with equivalent amounts of PC.
To study the effect of SA-PC liposomes on L. donovani
promastigotes, freshly transformed promastigotes of L. dono-
vani AG83 (106/450 ml of medium 199 containing 10% fetal
bovine serum) were incubated with 50 ml of PBS or various
concentrations of 22 mol% SA-PC liposomes at 37°C for 60
min, and their viability was determined microscopically by
erythrocin B stain exclusion. More than 99% of the parasites
were killed when incubated with 132 mg of SA-PC liposomes
per ml, and very weak activity was detected at 6.6 mg of lipid
per ml (Table 1). The number of viable promastigotes treated
with similar amounts of PC liposomes (data not shown) as well
as without liposomes appeared to be unchanged.
In vitro parasite killing by SA-PC liposomes was investigated
with murine peritoneal macrophages (106 cells) infected with
L. donovani promastigotes at a ratio of 1:10 at 37°C. Following
infection for 3 h, the macrophages were treated with graded
dosages of PC and 22 mol% SA-PC liposomes for 3 h. While
66% of the intracellular parasites were killed by 1,188 mg of
SA-PC liposomes per ml, in comparison to untreated infected
macrophages, no killing due to PC liposomes at similar con-
centrations was seen (Fig. 1A). The kinetics of antileishmanial
activity of 22, 44, and 88 mg of SA-PC liposomes per ml (doses
close to the 50% effective dose and lower) on infected macro-
phages revealed significant suppression of the parasites with
increasing concentrations of lipid, with 88 mg of SA-PC lipo-
somes per ml causing 95% killing of intracellular amastigotes
in 24 h (Fig. 1B). Similar concentrations of PC liposomes had
no significant effect on parasite multiplication.
To examine the therapeutic efficacy of SA-PC liposomes,
female BALB/c mice (4 to 6 weeks old) were each infected
intravenously (i.v.) with 2.5 3 107 promastigotes, freshly trans-
formed in a biphasic medium consisting of medium 199 and
blood agar. After 1 h of infection, the mice were randomly
assigned to five groups; the first group was injected i.v. with
PBS and used as a control group. The second group was
treated i.v. with a single dose of 22 mg of 22 mol% SA-PC
liposomes/animal (880 mg/kg of body weight). The third group
was similarly treated with a single dose of 55 mg of SA-PC
liposomes/animal (2,200 mg/kg of body weight). The fourth
and the fifth groups were injected with single doses of 20 and
50 mg of only PC liposomes/animal (800 and 2,000 mg/kg of
body weight), respectively. Three mice from each group were
sacrificed on days 30 and 60 postinfection, and the liver para-
site burden was determined as Leishman-Donovan units (the
number of amastigotes per 1,000 cell nuclei 3 organ weight [in
milligrams]) (1). In another set of experiments, BALB/c mice
were first infected for 8 weeks and then given single- and
multiple-dose liposome therapy. For the single-dose therapy,
the mice were injected with 55 mg of SA-PC liposomes/animal;
in the multiple-dose experiment, the animals received four
doses of 22 mg of SA-PC liposomes/animal/day on alternate
days. In parallel, groups of mice received a single dose of 50 mg
of PC liposomes or four doses of 20 mg of PC liposomes/
animal/day or PBS as a control. Mice were sacrificed on days 1,
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15, and 30 posttreatment, and the levels of amastigotes in the
liver and the spleen were estimated.
Single doses of both 22 and 55 mg of 22 mol% SA-PC
liposomes induced a significant reduction in the liver parasite
burden at days 30 and 60 postinfection, while PC liposomes (20
or 50 mg) alone had no effect (Fig. 2). BALB/c mice first
infected for 8 weeks and then treated with a single dose of 55
mg of SA-PC liposomes showed significant reductions in the
liver parasite burden—36% (P , 0.001), 53% (P , 0.001), and
68% (P value much less than 0.001)—and the splenic parasite
burden—23% (P , 0.01), 47.7% (P , 0.001), and 79% (P
value much less than 0.001)—at days 1, 15, and 30 posttreat-
ment, respectively, compared to controls (Fig. 3). Correspond-
ingly, on days 15 and 30 posttreatment, there were reductions
in the weights of the livers—20.8% (P , 0.001) and 32.5% (P
value much less than 0.001)—and spleens—33% (P , 0.001)
and 55.5% (P value much less than 0.001)—in the SA-PC
liposome-treated mice compared to controls (Fig. 3). A similar
dose of PC liposome treatment had no significant effect (P .
0.05) on hepatic and splenic parasite burdens and hepato-
splenomegaly in comparison to the results for controls. Treat-
ment of BALB/c mice with four doses of 22 mg of SA-PC
liposomes/animal on alternate days induced the suppression of
hepatic and splenic parasites to levels not significantly different
from those induced by a single dose of 55 mg of SA-PC lipo-
somes/animal (data not shown).
The toxicity of SA-PC liposomes for normal murine macro-
phages was investigated by measuring lactate dehydrogenase
activity in the culture medium of liposome-treated macro-
TABLE 1. Effects of SA-PC liposome concentrations on
L. donovani promastigotesa
Treatment and final
concn(mg/ml)
Promastigote
viability (%)
Control ...........................................................................................100
SA-PC liposomes
6.6............................................................................................ 94.0
13.2............................................................................................ 53.5
33.0............................................................................................ 27.3
66.0............................................................................................ 7.9
132.0............................................................................................ 0.5
a Promastigotes (106/450 ml) were incubated with various concentrations of 22
mol% SA-PC liposomes for 1 h at 37°C.
FIG. 1. (A) Effect of SA-PC liposomes on the survival of L. donovani amastigotes in mouse peritoneal macrophages. Cells were infected with L. donovani
promastigotes and incubated with various concentrations (13.2 to 1,188 mg/ml) of SA-PC liposomes or PC liposomes prepared with equivalent concentrations of PC.
Infected control macrophages contained 6.5 6 0.26 amastigotes/macrophage. (B) Microbicidal effect of SA-PC liposomes on L. donovani-infected macrophages as a
function of time. Macrophages were infected with L. donovani promastigotes and incubated with 22, 44, and 88 mg of SA-PC liposomes per ml for 0 to 96 h. Control
infected cells were treated only with media. The results, expressed as mean 6 standard deviation (n 5 3), are those of one experiment representative of three performed.
FIG. 2. Long-term activity of SA-PC liposomes against recent L. donovani
infection. Mice were infected i.v. with freshly transformed promastigotes and
treated i.v. 1 h later with 22 or 55 mg of SA-PC liposomes or with 20 or 50 mg
of PC liposomes without SA. Control infected animals were injected with PBS.
The liver parasite burden, expressed as Leishman-Donovan units, was estimated
at days 30 and 60 postinfection. Data shown are the mean 6 standard error from
one experiment representative of two performed.
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phages (8). SA-PC liposomes at 1,188 and 396 mg of lipid per
ml imparted 16.6 and 14.4% toxicity to normal macrophages,
respectively, while 132 mg of SA-PC liposomes per ml showed
less than 1% toxicity, as determined by the release of lactate
dehydrogenase. Lower concentrations of SA-PC vesicles (66 to
13.2 mg/ml) had no toxic effect on in vitro-cultured macro-
phages.
Estimation of specific levels of enzymes, such as serum al-
kaline phosphatase and glutamine pyruvate transaminase
(SGPT), related to normal liver function, at days 15 and 30
after injection of a single dose of 50 mg of PC liposomes or 55
mg of SA-PC liposomes revealed levels of alkaline phospha-
tase close to the normal levels. The level of SGPT increased
with SA-PC treatment by day 15. This increase in SGPT, which
was just above the normal range (5 to 35 U/ml), was reduced
to the normal levels by day 30. Blood parameters, such as
erythrocyte and leukocyte levels and hemoglobin content, and
histological examinations of spleen and liver indicated the ab-
sence of toxicity with SA-PC liposomes under the given con-
ditions (data not shown).
In this paper, we report on the remarkable in vitro and in
vivo activities of positively charged liposomes against L. dono-
vani parasites. Liposomes prepared with PC and SA had strong
cytolytic activity toward L. donovani promastigotes and intra-
cellular amastigotes, in comparison to the results obtained with
similar treatment with PC liposomes and control treatment.
The leishmaniacidal effect of these vesicles could be extended
to in vivo infections with L. donovani, with a single dose of 55
FIG. 3. Antileishmanial activity of a single dose of SA-PC liposomes in established experimental visceral leishmaniasis. BALB/c mice infected for 8 weeks were
treated i.v. with 55 mg of SA-PC liposomes or with 50 mg of PC liposomes. Control infected animals were injected with PBS. Mice were sacrificed 1, 15, and 30 days
after completion of treatment. The liver and spleen parasite burdens, expressed as Leishman-Donovan units (A), and weights of the liver and the spleen (B) were
measured. Data shown are the mean 6 standard error from one experiment representative of two performed.
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mg of SA-PC lipid showing effective therapeutic activity for
recent as well as established infections. The decline in the liver
and splenic parasite burdens corresponded with a significant
reduction in hepatomegaly and splenomegaly. This dose of
SA-PC liposomes, however, was not toxic to the host.
The leishmaniacidal activity of SA-PC liposomes for intra-
cellular amastigotes may be due to their preferential uptake by
macrophages (12, 14) followed by their cytotoxic action on the
parasites in the vacuoles. Leishmania parasites reside in the
macrophages of the liver, spleen, and bone marrow, cells which
are also responsible for the clearance of liposomes from the
blood. The affinity of positively charged liposomes for the
macrophages of the reticuloendothelial system is enhanced
through interactions with serum (12), to which the liposomes
are delivered, probably through the endocytic pathway. The
adsorption or binding of liposomes to macrophages may be
facilitated through nonspecific, electrostatic interactions of
positively charged liposomes with the negatively charged cell
membrane (10), followed by endocytosis (13, 22). Endosomes
fuse with lysosomes, which then fuse with parasitophorous
vacuoles, bringing liposomes into contact with parasites (2).
While the mechanism of killing of parasites by SA-PC lipo-
somes is not clear, it most probably occurs through direct
interactions of the liposomes with the parasites, which could
occur only if the SA-PC liposomes bypassed the fusion of the
vesicles with the cells. Although cationic liposomes containing
a neutral helper lipid, dioleoyl phosphatidylethanolamine, fuse
with anionic endosomes (21), vesicles without dioleoyl phos-
phatidylethanolamine are pH resistant, and fusion with cells
rarely occurs (22). Rather than fusing, it is possible that SA-PC
liposomes persist for a long time and induce intracellular
amastigote killing (Fig. 1 and 3). The interaction of liposomes
with leishmanial parasites may occur through sialic acid (16)
and lipophosphoglycan (7, 11), surface membrane components
which contribute considerably to the negative charge.
In summary, the leishmaniacidal activity of SA-bearing pos-
itively charged liposomes and their low toxicity toward host
cells warrant further investigation. Inclusion of antileishmanial
drugs in these vesicles may target a disease synergistically,
providing a new way to study liposome-mediated therapy of
leishmaniasis.
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